Post-Marketing Commitments and Post-Authorization Safety Studies (PASS) in Phase 4 Trials

Published on 21/12/2025

Understanding PMCs and PASS in Phase 4 Clinical Trials: Compliance and Design Essentials

Table of Contents

What Are Post-Marketing Commitments and PASS?

After a new drug or biologic is approved, regulatory agencies often require further studies to confirm its long-term safety, effectiveness, or optimal usage. These obligations fall under two categories: Post-Marketing Commitments (PMCs) and Post-Authorization Safety Studies (PASS). Both are conducted during Phase 4 and play a crucial role in lifecycle drug management.

While PMCs may be voluntarily undertaken or required, PASS is usually mandated by regulators when there is a known or potential safety concern. These studies ensure that drugs continue to offer favorable benefit-risk ratios in real-world populations.

Why PMCs and PASS Are Important

Validate real-world safety: Confirm risk profiles in broader populations
Fulfill regulatory obligations: Comply with EMA, FDA, CDSCO, PMDA, etc.
Support pharmacovigilance programs: Collect long-term adverse event data
Enable label updates or withdrawal: Modify indication, dosage, or risk warnings

Types of Post-Marketing Commitments

1. Clinical PMCs

Confirmatory efficacy trials (e.g., for conditional approvals)
Studies in special populations (e.g., pediatric, geriatric)

2. Non-Clinical PMCs

Carcinogenicity, reproductive toxicity, or drug interaction studies

3. Chemistry, Manufacturing, and Controls (CMC) PMCs

Stability studies, validation of manufacturing processes

What Constitutes a PASS?

PASS is a type of post-authorization

study designed to monitor safety and detect known, potential, or emerging risks associated with a product. It can be initiated by:

Regulators (obligatory or “imposed” PASS)
Sponsors (voluntary or “agreed” PASS)

Examples of PASS Triggers

Unexpected adverse events in early trials
Use in vulnerable populations (e.g., pregnant women)
Need to confirm effectiveness of risk minimization strategies

Study Designs Commonly Used

For PMCs:

Randomized or open-label interventional trials
Dose-finding or titration studies

For PASS:

Prospective observational cohort studies
Case-control or nested case-control studies
Drug utilization studies (DUS)
Patient registries or database analysis

PASS Registration and Transparency

EU: All imposed and voluntary PASS must be registered in the EU PAS Register
FDA: PMRs and PMCs must be listed in Drugs@FDA and tracked annually
PMDA: PASS submissions required for conditional or early approvals

Examples of PMCs and PASS in Practice

PMC Example:

A sponsor received FDA approval for a biologic based on Phase 2 efficacy. A confirmatory Phase 4 trial in a broader population was a required PMC. The sponsor submitted data within 3 years, confirming efficacy and leading to full approval.

PASS Example:

EMA required a PASS for a newly approved antipsychotic due to potential cardiac risk. A 5-year observational study involving 10,000 patients assessed QT prolongation and sudden cardiac death, with outcomes leading to a black box warning update.

Reporting and Compliance Timelines

FDA: Annual status reports on all PMRs and PMCs
EMA: Protocol approval before study initiation; final report timelines depend on risk
CDSCO (India): Requires PSURs every 6 months for the first 2 years post-approval

Challenges and Solutions

Challenge: Delays in study initiation or reporting
Solution: Develop internal regulatory trackers and escalation protocols
Challenge: Low engagement in long-term observational studies
Solution: Use mobile apps, home visits, and patient portals to maintain engagement
Challenge: Data harmonization across regions
Solution: Use global data standards (CDISC, MedDRA) and centralized databases

Best Practices for Executing PMCs and PASS

Engage with regulatory authorities early to align study objectives
Choose pragmatic and scalable study designs
Use validated tools for adverse event collection and signal detection
Maintain transparency through public registries

Final Thoughts

Post-Marketing Commitments and PASS are not just regulatory formalities—they are essential tools for ongoing patient safety and data-driven therapeutic improvements. Successfully navigating these Phase 4 obligations requires proactive planning, cross-functional collaboration, and a deep understanding of evolving regulatory expectations.

At ClinicalStudies.in, we support pharmaceutical professionals in the strategic design, execution, and compliance management of Phase 4 post-marketing studies across global markets.